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The purpose of the study was to evaluate the influence 
of calcium phosphate (CAP) and polyethylene glycol 
(PEG) particles on the systemic delivery of insulin ad-
ministered by the pulmonary route. Two methods of 
pulmonary delivery were employed: intratracheal instil-
lation and spray instillation. Insulin-CAP-PEG particles 
in suspension (1.2 U/kg, 110-140 μL) were administered 
to the lungs of fasted rats by intratracheal instillation 
(INCAPEG) or spray instillation (SINCAPEG). Control 
treatments consisted of insulin solution (1.2 U/kg) by 
intratracheal instillation, spray instillation, and subcuta-
neous administration (SC). Plasma concentrations of 
insulin and glucose were determined by chemilumines-
cence and colorimetric methods, respectively. Data were 
analyzed by compartmental and non-compartmental 
methods, and pharmacokinetic (PK) and pharmacody-
namic (PD) parameters of insulin disposition were de-
termined. PK analysis suggested that insulin adminis-
tered in particles had a longer half-life, a longer mean 
residence time, and a smaller rate of elimination than 
insulin in solution. In addition, insulin bioavailability 
after SINCAPEG was 1.8-fold that of insulin solution 
administered SC. PD analysis showed that smaller areas 
under the effect curve and, conversely, larger areas 
above the effect curve were obtained after INCAPEG in 
comparison to insulin solution. The magnitude of this 
effect was increased after SINCAPEG. The presence of 
CAP-PEG particles appears to positively influence the 
disposition of insulin administered to the lungs of Spra-
gue-Dawley rats. Spray instillation appears to be a more 
efficient method of delivering insulin to the lungs of rats 
than intratracheal instillation. 
 
INTRODUCTION 
The reduced bioavailability observed after the administra-
tion of inhaled insulin has been a major concern for the 
pulmonary delivery of insulin. Several approaches, includ-
ing the use of co-administration of permeation enhancers 
or delivery agents and encapsulation of insulin in proprie-
tary particles, have been used to increase the bioavailabil-
ity of inhaled insulin. We have previously reported that co- 
administration of insulin with the delivery agent hydroxy-
methyl amino propionic acid (H-MAP) significantly im-
proved the bioavailability of insulin in the rat lung in a 
dose-dependent fashion and without adverse effects in 
lung histology and function.1,2 Other insulin particle tech-
nologies, including Technospheres™ (Pharmaceutical 
Discovery Corporation, Elmsford, NY),3 ProMaxx® (Epic 
Therapeutics, Inc, Norwood, MA),4 SoliDose® (Elan 
Drug Delivery, Nottingham, England),5 and AIR™ tech-
nology (Alkermes, Cambridge, MA)6-8 have been devel-
oped as aids to pulmonary drug delivery. These vary in 
composition and purpose. In general, they employ compo-
nents generally regarded as safe (GRAS) from a regulatory 
standpoint and are intended to enhance targeted and/or 
controlled delivery of drug. 
The particles used in the present study also employ GRAS 
excipients: calcium phosphate (CAP) and polyethylene 
glycol (PEG). They are prepared by a controlled precipita-
tion technique9 that yields solid particles in a uniform mi-
cron size range. Their influence on drug disposition from 
the lungs of rats has not previously been described. CAP 
particles have shown high loading capacities and a poten-
tial for controlled drug release. The inclusion of PEG in 
the formulation improved insulin loading capacity, possi-
bly by masking surface negative charges in the CAP parti-
cles due to the presence of PO4 ions.9 Other reports also 
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indicate enhanced protein absorption for polymeric mi-
croparticles10 and hydrogels11 in the presence of PEG. 
Historically, accurate dose delivery to laboratory ani-
mals has been difficult to achieve. Previous studies have 
employed intratracheal instillation or spray instillation. 
The goal of the present study was to evaluate the influ-
ence of CAP-PEG particles on the systemic delivery of 
insulin administered by the pulmonary route. In addition, 
2 methods of delivery, intratracheal liquid instillation 
and spray instillation, were compared to assess their ef-
fect on delivery. A study of the effects of these particles 
on insulin disposition in the rat model will assist in 
evaluating the particles' prospects for enhancing delivery 
of this drug, using the respiratory tract as a route of ad-
ministration. 
 
MATERIALS AND METHODS 
Materials 
Recombinant human insulin expressed in Escherichia 
coli (28.6 USP units/mg) was obtained from Sigma 
Chemical Co (St Louis, MO). Insulin-CAP-PEG parti-
cles were manufactured by BioSante Pharmaceuticals, 
Inc (Smyrna, GA) as a 0.58 mg/mL insulin suspension 
(1 mg of solids per mL of suspension). The mean vol-
ume diameter was 0.315 μm and was determined by 
photon correlation spectroscopy using a Beckman N4 
Plus submicron particle sizer (Brea, CA). Sterile saline 
solution (Abbott Laboratories, North Chicago, IL) was 
used to replace the blood volume taken during sampling. 
Sodium heparin injection (1000 USP U/mL, Elkins-
Sinn, Inc, Cherry Hill, NJ) was used after dilution with 
sterile saline (15 U/mL); a fresh supply was prepared 
each day of the study. Ketamine, acepromazine (Fort 
Dodge, Fort Dodge, IA), and xylazine (Phoenix Scien-
tific Inc, St Joseph, MO) were used in the appropriate 
doses for anesthesia. 
 
Preparation of Insulin Solution or Suspension 
Insulin solution was prepared by dissolving recombinant 
human insulin powder in 2 mL of water for injection 
(WFI) pH 3. Hydrochloric acid (0.1N) was added in 30 
μL increments until solution was achieved. Subse-
quently, 3 mL of WFI pH 7.4 was added, and the pH 
was adjusted to physiological pH (7.4) with 0.1N so-
dium hydroxide solution. The final volume for the de-
sired concentration was achieved with additional WFI. 
Insulin-CAP-PEG particles were prepared by BioSante 
according to the standard operating procedures. Briefly, 
1 volume of insulin from a stock solution of 20 mg/mL 
in 0.01N HCl was diluted to 1 mg/mL in 1% (wt/vol) 
PEG3350. One volume of calcium chloride (125 mM) and 
0.2 volume of sodium citrate (156 mM) were injected into 
PEG-hIns solution, simultaneously, while stirring. One 
volume of 125 mM sodium dibasic phosphate was added 
to initiate the formation of calcium phosphate. Stirring was 
continued for 48 hours at room temperature for maximum 
insulin incorporation. The resulting particle suspension 
was sonicated at 5 to 10°C to obtain stable particles in the 
size range of 2 to 4 μm. Working CAP-PEG incorporated 
insulin doses were prepared by diluting the supplied sus-
pension with WFI until the desired insulin concentration 
was achieved. All solutions and suspensions were pre-
pared immediately prior to administration into animals. 
 
Droplet Size Determination 
The droplet size of the spray emerging from the spray in-
stillator (Penn Century, Philadelphia, PA) was measured 
using a laser diffraction instrument (Malvern 2600c, 
Southborough, MA) fitted with a 63-mm lens (0.5- to 118-
μm size range) and an external timing trigger. The meas-
urement was synchronized with spray emission from the 
Penn Century device. Insulin solutions and suspensions 
were measured in a Hamilton syringe (Hamilton Com-
pany, Reno, NV) and attached to the spray instillator. The 
device was positioned at 4 cm from the laser beam (the 
aerosol plume center was projected across the laser). Parti-
cle size data were collected throughout the passage of the 
spray through the laser region. The positioning of the de-
vice in this study was such that the orifice of the micros-
prayer was within the lens cut-off distance, the device did 
not deposit aerosol droplets on the detector lens surface, 
and the actuator orifice was aligned with the height of the 
laser path. Particle size estimates were based on Fraun-
hofer diffraction theory. 
 
Animals 
Female Sprague-Dawley rats (Hilltop Laboratory Animals 
Inc, Scottdale, PA) weighing 227-284 g were housed in a 
12-hour light/12-hour dark cycle and constant temperature 
environment of 22°C. A standard diet (Prolab RMH 3000, 
PMI Nutrition International, Inc, Brentwood, MO) and wa-
ter were supplied ad libitum during a period of acclimatiza-
tion. However, animals were fasted 10.5 to 12 hours before 
dosing. All animal procedures were approved by the Institu-
tional Animal Care and Use Committee of the University of 
North Carolina, an American Association for Accreditation 
of Laboratory Animal Care (AALAC) approved facility. 
The day of the study, each rat underwent cannulation of the 
right external jugular vein with silicone polymer tubing 
 2
AAPS PharmSci 2003; 5 (2) Article 9 (http://www.pharmsci.org). 
Table 1. Summary of Treatments* 
Group Route Formulation Delivery Device Insulin Dose Group Code 
Number of Ani-
mals 
A Subcutaneous Insulin solution Injection 1.2 U/kg SC 6 
B Intratracheal Insulin solution Liquid instillation 1.2 U/kg ITI 6 
C Intratracheal Insulin-CAP-PEG sus-pension Liquid instillation 1.2 U/kg INCAPEG 7 
D Intratracheal Insulin solution Spray instillation 1.2 U/kg SI 6 
E Intratracheal Insulin-CAP-PEG sus-pension Spray instillation 1.2 U/kg SINCAPEG 8 
F Intratracheal Empty CAP-PEG sus-pension Liquid instillation None — 5 
G Subcutaneous Empty CAP-PEG sus-pension Injection None — 2 
H Untreated con-trols None None None — 2 
*CAP-PEG indicates calcium phosphate–polyethylene glycol particles; SC, subcutaneously; ITI, insulin solution by intratracheal instillation; SI, insu-
lin solution by spray instillation; INCAPEG, insulin CAP-PEG particles by intratracheal instillation; SINCAPEG, insulin CAP-PEG particles by spray 
instillation.  
 
connected to polyethylene PE-50 tubing. The surgery was 
performed after anesthetizing animals with an intraperito-
neal injection of ketamine:xylazine:acepromazine cocktail 
(50:3.4:3.3 mg/kg, respectively). The cannula was routed 




Animals were randomly divided into 8 groups to receive 
different treatments (Table 1). One group received insu-
lin solutions administered subcutaneously to the right 
thigh of each rat. Some other groups received insulin 
solution or suspension by intratracheal liquid instillation 
or spray-instillation. The procedure involved intubating 
animals approximately 1 hour after surgery, using a fiber 
optic laryngoscope (Dolan-Jenner Industries Inc, Law-
rence, MA). The tip of the delivery device (oral gavage 
needle or spray instillator) was placed at the level of the 
tracheal bifurcation to the main bronchi. Suspensions or 
insulin solution (110-140 μL) were instilled/sprayed into 
the lower airways of the rats using a Hamilton syringe 
attached to the delivery device. After administration, the 
delivery device was removed and the animal was held in 
an upright position for 1 minute to ensure deposition of 
the dose. After this period, the animal was placed on its 
side until recovery from anesthesia, approximately 1.5 
hours after dosing. From that point on, animals were free 
to move in their cages. Each animal's respiration was 
monitored visually until the animal recovered from anes-
thesia. In addition to the experimental groups receiving 
insulin solutions or suspensions, 3 groups were studied as 
negative controls. These animals received empty CAP-
PEG suspensions SC, by intratracheal instillation or spray 
instillation or were untreated controls (Table 1). The sta-
bility of the glucose baseline was verified by measuring 
glucose levels at 3 time points before insulin administra-
tion: immediately on completion of surgery, 15 minutes 
before dosing, and immediately before dosing. 
Blood samples (450 μL) were collected from each animal 
into clean Eppendorf tubes previously coated with Sigma-
cote™ (Sigma Chemical Co, St. Louis, MO) (to avoid in-
sulin adsorption onto the tube walls) at 0, 0.17, 0.5, 1, 1.5, 
2, 3, 4, 5, 6, 7, 8, and 12 hours. Sterile saline solution was 
used to replace the blood volume lost through sample col-
lection. Blood samples were immediately centrifuged and 
serum was collected into clean Eppendorf tubes previously 
coated with Sigmacote™. Samples were stored at -80°C 
until analyzed. The body temperature of each animal was 
maintained at 37°C using heated surgical pads and incan-
descent lamps to prevent hypothermia during anesthesia. 
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After recovery from anesthesia, animals were placed in 




The glucose concentration in serum samples was deter-
mined using the VT 250 automatic chemical analyzer 
(Johnson & Johnson Clinical Diagnostics Inc, Rochester, 
NY). Analysis is based on the enzyme-catalyzed reac-
tion of glucose with molecular oxygen, followed by a 
second reaction that produces a highly colored red dye. 
The intensity of the color is proportional to the quantity 
of glucose in the sample. This analytical method deter-
mines plasma glucose concentrations in the range of 20 
to 450 mg/dL with a ±2% precision. 
Insulin Determination 
Insulin serum concentrations were determined by the 
Beckman Access Ultrasensitive Insulin Assay, which is 
a simultaneous one-step immunoenzymatic ("sandwich") 
assay performed by the automated Access Immunoassay 
System (Beckman Coulter, Brea, CA). A sample (20 
μL) was added to a reaction vessel with mouse mono-
clonal anti-insulin alkaline phosphatase conjugate and 
paramagnetic particles coated with mouse monoclonal 
anti-insulin antibody. A chemiluminescent substrate, 
Lumi-Phos 530, was added to the reaction vessel, and 
light generated by the reaction was measured with a lu-
minometer. The photon production is proportional to the 
amount of conjugate bound to the solid support. The 
amount of analyte in the sample was determined by 
means of a stored, multipoint calibration curve. This 
assay is linear in the interval of 1 to 300 μIU/mL with a 
±5% precision.  
 
Data Analysis  
Pharmacokinetic Analysis 
Insulin plasma concentration-time data was initially ana-
lyzed by fitting the data to a one-compartment body 
model, first order absorption, first order elimination, no 
lag time for all treatments using the WinNonlin com-
puter analysis program (Pharsight Corp., Mountain 
View, CA): 
C = D Ka / V / (Ka – K) * (EXP(–KT) – 
                   EXP(KaT)) 
(1)
The following pharmacokinetic (PK) parameters were 
obtained: area under the plasma concentration-time 
curve (AUC), maximum insulin concentration (Cmax), time 
to obtain Cmax (Tmax), first order absorption constant (Ka), 
and first order elimination constant (K). The criteria to 
determine the best fitting curve were the Akaike criteria, 
the model selection criteria, the coefficient of variation, 
and the width of the confidence interval for each parame-
ter estimate. 
Insulin data were subsequently analyzed by non-
compartmental methods (LaGran computer analysis pro-
gram12) to obtain AUC, area under the first moment curve, 
apparent total body clearance (CL), mean residence time 
(MRT), and half-life (T1/2). Estimates of K were obtained 
by supplying the program with the number of points in the 
terminal phase of the concentration versus time plots. Cmax 
and Tmax were determined from the non-fitted plasma ver-
sus time profiles for each animal. The relative bioavailabil-
ity (F) was calculated using the following equation: 
100
0   *  
Dose















The percentage minimum plasma glucose concentration 
(%MPGC) and the time to obtain each %MPGC 
(T%MPGC) were determined from the mean plasma glucose 
level versus time profile for the treatments. The area 
above the effect curve (AACE) was calculated by: 
AACE = Total Area – AUCE (3)
The area under the effect curve (AUCE) was calculated 
by the trapezoidal rule. 
The percentage total reduction in plasma glucose 











AAC  *  TRPG% 8-0  (4)
 
Statistical Analysis 
Data were analyzed with analysis of variance and the 
least-squares significant-differences multiple comparison 
method. A probability level of <0.05 was considered to 
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Figure 1. Serum concentration versus time curves after administration of insulin solution 
(1.2 U/kg) by the subcutaneous (SC) or intratracheal routes: liquid instillation (ITI) or 
spray-instillation (SI) and insulin-CAP-PEG particles by intratracheal route: liquid instilla-
tion (INCAPEG) or spray-instillation (SINCAPEG) (mean ± SD, n = 4-8). Asterisk indi-
cates significantly different from SC and SI insulin solution (P < 0.05). 
 
RESULTS 
Droplet Size Determination 
The droplet size of the spray emerging from the Penn 
Century was 45.5 ± 3.7 μm (n = 7) as estimated by la-
ser diffraction. There was no significant difference in 
the droplet size as a consequence of sprayed volume. 
 
Pharmacokinetic Data Analysis 
Figure 1 shows the plasma concentration versus time 
curves after administration of insulin solution (1.2 U/kg) 
or suspensions by the different routes. Significantly, the 
highest insulin plasma concentrations were obtained at 
all time points after spray instillation of insulin-CAP-
PEG particles (SINCAPEG). Although higher insulin 
concentrations were observed in animals treated SC dur-
ing the first hour, they were comparable until 6 hours for 
all insulin treatments. After 6 hours, insulin concentra-
tions were under the analytical detection limits for all 
groups receiving solutions but remained detectable in 
groups receiving insulin particles. Insulin concentrations 
after SI were notably higher than those after ITI for the 
first 2 hours, but they were comparable for the remainder 
of the study. Likewise, insulin concentrations after particle 
administration were significantly higher following spray 
instillation (SINCAPEG) than they were following liquid 
instillation (INCAPEG). 
Tables 2 and 3 show a summary of the PK parameters 
obtained by compartmental and non-compartmental analy-
sis, respectively. Smaller standard deviations associated 
with parameter estimation were observed when calculated 
by non-compartmental methods. The Ka of insulin solution 
ITI was significantly faster than that by SC or that after 
administration of particles (INCAPEG, SINCAPEG). In-
sulin solution administered SC was eliminated (K) signifi-
cantly faster than by intratracheal delivery (ITI or SI). Fur-
thermore, insulin was eliminated significantly faster when 
administered in solution (SC, ITI, or SI) than in particles 
(INCAPEG, SINCAPEG). The clearance rate was signifi-
cantly higher for insulin solution ITI, and it was compara-
ble for the rest of the experimental groups. This probably 
reflects its dependency on the absorption process. Com
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Table 2. Summary of the Pharmacokinetic Parameters Obtained by Compartmental Analysis After Administration 

























(μU.h/mL) 149.73  14.62
2 54.05  12.544 109.84  11.233 76.54  33.433,4 260.89  35.191 
Ka (h
–1) 3.96  2.402 48.16  28.571 13.79  4.762 8.31  8.362 4.66  1.912 
K (h–1) 2.32  0.721 1.52  0.562 1.05  0.112,3 0.92  0.182, 3 0.88  0.163 
T½ (h) 0.33  0.123 0.52  0.222, 3 0.67  0.072 0.78  0.131 0.86  0.181 
Cmax 
(μU/mL) 168.10  38.01
1 76.83  38.092 88.28  9.802 54.54  24.962 150.92  34.941 
Tmax (h) 0.35  0.101,2 0.10  0.053 0.21  0.062,3 0.39  0.191 0.43  0.081 
F — 0.29  0.183 0.70  0.052 0.57  0.212,3 1.74  0.241 
*Numeric superscripts show the relative rank (starting from the highest values).  When the means are not significantly different, the same 
superscript is used.  
 
 
Table 3. Summary of the PK Parameters Obtained by Non-compartmental Analysis After Administration (SC, intra-

























(μU.h/mL) 158.00  15.48
2 49.16  17.334 115.04  21.293 99.04  23.953 297.10  37.011 
CL x 10–3 
(mL/hkg) 0.01  0.00
2 0.06  0.061 0.011  0.0022 0.01  0.002 0.004  0.0012 
K (h–1) 0.80  0.211,2 0.66  0.112 0.94  0.341 0.22  0.053 0.37  0.073 
T½ (h) 0.93  0.253 1.08  0.223 0.82  0.323 3.25  0.871 1.93  0.372 
MRT (h) 0.89  0.173 1.08  0.173 1.06  0.053 2.64  0.901 1.97  0.212 
Cmax 
(μU/mL) 166.15  20.75
1 54.60  23.492 85.87  11.262 58.53  23.622 164.6  39.001 
Tmax (h) 0.39  0.171,2 0.22  0.142,3 0.17  0.003 0.37  0.181,2 0.50  0.001 
F — 0.31  0.113 0.66  0.052 0.63  0.152 1.88  0.231 
*Numeric superscripts show the relative rank (starting from the highest values).  When the means are not significantly different, the 
same superscript is used.  
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Figure 2. Percentage of plasma glucose reduction from baseline versus time curves after ad-
ministration of insulin solution (1.2 U/kg) (mean ± SD, n = 4-8) by the subcutaneous (SC) or 
intratracheal routes: liquid instillation (ITI) or spray-instillation (SI) and insulin-CAP-PEG 
particles by intratracheal route: liquid instillation (INCAPEG) or spray-instillation 
(SINCAPEG). Asterisk indicates significantly different from SC and SI insulin solution (P < 
0.05); double asterisk, significantly different from SC solution (P < 0.05). 
 
partmental analysis indicated that the insulin half-life in 
animals receiving particles intratracheally using either 
device was significantly longer than solution administra-
tion using either device or route. In addition, non-
compartmental analysis revealed that the half-life and 
MRT of INCAPEG were statistically longer than those 
of SINCAPEG. Insulin Cmax was comparable in animals 
receiving solution SC or SINCAPEG and significantly 
higher than those of groups receiving SI or ITI solution 
or INCAPEG. Tmax was reached faster after SI of insulin 
solution. Tmax values were similar after administration 
SC or ITI of insulin solution and significantly longer 
after SINCAPEG. AUC was significantly largest for 
animals that received SINCAPEG, followed by those 
that received solution SC. Relative bioavailability (F) 
after SINCAPEG was 1.74-fold (compartmental analy-
sis) and 1.88-fold (non-compartmental analysis) that 
after administration SC of insulin solution. 
Pharmacodynamic Data Analysis 
Figure 2 shows the percentage plasma glucose reduction 
from baseline versus time curves after administration of 
insulin (1.2 U/kg) solutions or suspensions by the different 
routes. A rapid and large initial decrease in glucose levels 
was observed after administration of insulin SC, SI, and 
SINCAPEG. However, the %MPGC achieved was smaller 
after SI and INCAPEG than for other groups. Glucose lev-
els remained significantly lower after SINCAPEG than for 
other groups for the rest of the study (Figure 2). No sig-
nificant difference was observed in the levels of glucose 
from baseline levels among the 3 negative control treat-
ments. 
Table 4 shows the mean pharmacodynamic (PD) parame-
ters following administration of the different treatments. 
The calculated %MPGC was significantly smaller in rats 
receiving SI and comparable for other treatments. The 
T%MPGC was shorter for animals receiving insulin SC and 
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Table 4. Mean PD Parameters Obtained After Administration (SC, intratracheal instillation or spray instillation) of Insulin 






















%MPGC 42.38  7.161,2 39.54  5.431,2 34.85  3.732 44.24  11.831 38.24  8.011,2 
T%MPGC 0.83  0.262 1.25  0.271 1.00  0.001,2 1.4  0.541 1.38  0.441 
AUCE 692.32  11.271 678.68  51.751,2 667.50  28.501,2 611.94  59.692 486.50  73.703 
AACE 107.68  11.293 121.38  51.622,3 132.50  28.502,3 188.05  59.672 313.50  73.701 
%TRPG 15.58  1.872 21.8  4.352 20.0  5.202 27.79  14.682 67.40  23.301 
*Numeric superscripts show the relative rank (starting from the highest values). When the means are not significantly different, the same super-
script is used.  
 
comparable for animals receiving other treatments. The 
AUCE was significantly smaller after administration of 
SINCAPEG and significantly larger for animals receiv-
ing insulin SC. Likewise, AACE was significantly larger 
after administration of SINCAPEG and significantly 
smaller for animals receiving insulin SC. In addition, 





We have previously reported the dose-effect relationship 
of insulin contained in CAP-PEG particles over a range 
of doses (0.24-2.4 U/kg), supporting the potential use of 
CAP-PEG particles to increase the effectiveness of de-
livery through the lungs.13 The present study evaluated 
the influence of CAP-PEG particles on delivery and 
transport of insulin in the lungs of Sprague-Dawley rats 
compared to the traditional subcutaneous method of de-
livery and measured as enhancement of the PK and PD 
parameters. The effectiveness of 2 intratracheal delivery 
devices was also evaluated. 
Clinical data reported by Cefalu et al14 suggest that in-
haled insulin is safe over 2 years of use; however, the 
possibility of immunologic reactions to inhaled proteins 
and peptides is still a major concern. Preclinical studies 
conducted by BioSante15 reported minimum IgE re-
sponses to vaccine antigens formulated with CAP as an 
adjuvant and very little inflammation at the site of injec-
tion. Therefore, it is anticipated that therapeutic proteins 
formulated in CAP particles will invoke little or no IgE 
response relative to the responses that may be induced by 
other drug carriers. Also, earlier preclinical acute toxicity 
and inflammatory response studies of CAP (IIT Research 
Institute, Chicago, IL) using various routes of administra-
tion, including inhalation, reported no significant adverse 
effect at the administration sites as a result of 2 weeks-
exposure to CAP. In the same studies, bronchoalveolar 
lavage (BAL) assessment indicated no significant biologi-
cal effects on any protein or enzyme parameter in the BAL 
fluid of interim or terminal inhalation groups. Gonda16 
developed a mathematical model that describes the release 
of drug from a carrier deposited in the respiratory tract and 
the clearance of the drug by mucociliary and nonmuco-
ciliary mechanisms. This model also accounts for the pos-
sibility of accumulation of carrier materials during chronic 
administration as a function of release rate of the drug. 
According to the in vitro release profile of insulin from 
CAP-PEG particles (100% of insulin released in 18 hours 
and cumulative mass loss <40% during that period), it is 
unlikely that these particles would be resident for suffi-
cient time to pose a risk of toxicity. Nevertheless, all of 
these observations require experimental evaluation before 
definitive conclusions can be drawn regarding safety. 
Although several studies have demonstrated that inhaled 
insulin is absorbed faster in the presence of specific deliv-
ery aids than insulin delivered SC,17,18 the reduced 
bioavailability observed in all systems used for administra-
tion has been called insurmountable.18 The present study 
indicates that CAP-PEG particles significantly reduce the 
elimination (K) of insulin, increasing its systemic resi-
dence time (MRT and half-life). Thus, insulin bioavailabil-
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ity and duration of action are enhanced when adminis-
tered to the lungs compared to the SC route.  
The AUC of animals receiving SINCAPEG was almost 
twice that of the SC group. The insulin elimination rate 
(K) was significantly smaller when it was included in the 
CAP-PEG particles, which correlates with the longer 
MRTs and half-lives observed after administration of 
particles. Insulin half-life and MRT after SINCAPEG 
were respectively, 2- and 3-fold longer than after insulin 
SC (Table 3). This is also reflected in the significantly 
higher insulin serum concentrations observed from 1 to 
8 hours (Figure 1). The rate of appearance of insulin in 
serum correlated well with the in vitro release profiles of 
insulin from CAP-PEG particles.9 
The relative bioavailability of insulin in SINCAPEG 
was 1.74-fold (compartmental) and 1.88-fold (non-
compartmental) that of insulin SC. It should be noted 
that this relative bioavailability is almost 3-fold that ob-
served after INCAPEG, which may reflect a more effi-
cient dose distribution. This may be seen in Figures 1 
(better and faster absorption) and 2 (longer duration of 
action). Spray instillation may be more efficient than 
intratracheal instillation in delivering insulin particles 
because distribution of the dose after intratracheal instil-
lation is frequently localized (<5% of lung surface).17 
Insulin absorption after intratracheal instillation might be 
expected to proceed from coarse droplets or liquid de-
posited on a small fraction of the total surface area of the 
lung, whereas droplets produced by SI present a spray to 
many regions of the lung. 
The pharmacodynamics of insulin are complex and de-
pend on various factors such as route of administration, 
liver function, or glucose concentration. The hypogly-
cemic effect is based on the sum of several biochemical 
and physiological processes that occur at different sites. 
The practical solution to overcome this complexity is to 
monitor glucose levels and titrate patients according to 
the overall response to the administered insulin.19 Stud-
ies in humans have evaluated the effects of different in-
sulin formulations using the glucose clamp technique to 
maintain baseline levels.18, 20-22 However, in the present 
study the glucose baseline levels were maintained by 
fasting the animals 10.5 to 12 hours before and during 
the experiment.  
AUCE and AACE after administration of SINCAPEG or 
INCAPEG were both significantly different than those 
after insulin SC. In addition, %TRPG was significantly 
larger in animals receiving SINCAPEG than for any 
other treatment. Plasma glucose levels in animals receiv-
ing SINCAPEG remained lower for longer time periods 
than those in animals receiving any other treatment 
(Figure 2). The extended hypoglycemic effect of insulin-
CAP-PEG was comparable to that observed in a diabetic 
mouse model and could be explained by a sustained re-
lease of insulin from particles as observed in the in vitro 
release profile.9 
Patton et al17 defined the efficiency of aerosol insulin as a 
sum of the efficiency of the device, the efficiency of depo-
sition, and the efficiency of absorption. We acknowledge 
the fact that the 2 first terms were circumvented in the pre-
sent studies by directly spraying/instilling the dose into the 
rat's trachea. However, the efficiency of absorption should 
be optimized before deposition and device efficiency can 
be optimized. The high bioavailability observed with 
CAP-PEG particles (>170%) at the low dose of insulin 
evaluated in the present studies, is a promising observation 
with regard to the efficiency that might be achieved upon 
optimizing device and deposition characteristics. 
A number of studies have evaluated the efficacy of inhaled 
insulin. Comparisons among these studies become subjec-
tive, as there are many variables involved that can influ-
ence the evaluation of a particular approach. Among these 
variables are the type of insulin, formulation, dose, means 
of administration, and species employed. Human insulin 
tends to have faster rates of absorption from the site of 
subcutaneous administration and shorter duration of action 
compared with animal insulin.19 Likewise, it has been re-
ported that pulmonary bioavailability of insulin is underes-
timated in rats and overestimated in rabbits and monkeys 
when compared to that of humans.17  Table 5 summarizes 
the efficacy studies of insulin delivered through the lungs 
that are relevant for comparison to the present study.3-5, 7, 18, 
21-27 Among the studies that evaluate insulin formulations 
in rats using direct means of delivery, CAP-PEG particles 
yield the highest bioavailability using the smallest dose.  
In summary, insulin contained in CAP-PEG particles de-
livered intratracheally to Sprague-Dawley rats by intratra-
cheal instillation or spray instillation appeared to have a 
longer half-life and MRT and to be eliminated more 
slowly than insulin solution. Moreover, the selection of an 
appropriate delivery device significantly increased the ef-
ficiency of this approach. Results obtained in the present 
study may support the potential use of insulin-CAP-PEG 
particles to increase the effectiveness of drug delivery 
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Table 5. Efficacy Studies of Insulin Delivered Through the Lungs* 
Formulation Type of Insulin Dose Device Subject F (%) Tmax (min) Tglumin (min) 
Duration of Effect 
(h) 
Reference 









or MDI 3 Wistar rats 27-98



















human 5 U/kg Instillation 4 Wistar rats 20.24
‡ 10 120 4 (26) 
AIR particles 
(powder) NS 1.8 mg Insufflation 3 rats 87.5 — — 96 (7) 
Solidose parti-
cles (powder) NS 56 U/kg Insufflation Rats 50-100
§ — — — (5) 
ProMaxx parti-
cles (powder) Human — — Rats — — — 6 (27) 















NS 1.2 and 2.4 U/kg Inhalator M 6 beagle dogs — 11 and 7.5 30 — (3) 
 NS 100 U — 5 patients 25.8 — — — (21) 
 Regular human 100 U Inhalator M 5 patients 14.6# 13 39 5 (22) 
Liquid insulin Human soluble 1.2 U/kg AERx 18 diabetic patients 13
** 62 157 8 (18) 
*Tglumin indicates time to reach minimum glucose concentration; MDI, metered dose inhaler; NS, not specified; DPI, dry powder inhaler; 
† Depending on aerosol or instillation delivery and depth of intratracheal administration. 
‡ Calculated from intravenous instead of subcutaneous dose. 
§ Depending on the formulation tested. 
 Dog was fed at 200 minutes. 
¶ Lower value corresponds to intratracheal instillation and upper value to spray-instillation. 
# Calculated from area under the curve and subcutaneous and inhaled doses. 
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